KR100948469B1 - 뇌경색 질환 또는 ｃｎｓ 질환의 치료를 위한 약물로서의피페라진 벤조티아졸 - Google Patents

뇌경색 질환 또는 ｃｎｓ 질환의 치료를 위한 약물로서의피페라진 벤조티아졸 Download PDF

Info

Publication number
KR100948469B1
KR100948469B1 KR1020047016871A KR20047016871A KR100948469B1 KR 100948469 B1 KR100948469 B1 KR 100948469B1 KR 1020047016871 A KR1020047016871 A KR 1020047016871A KR 20047016871 A KR20047016871 A KR 20047016871A KR 100948469 B1 KR100948469 B1 KR 100948469B1
Authority
KR
South Korea
Prior art keywords
alkyl
benzothiazol
pyrimidin
methyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047016871A
Other languages
English (en)
Korean (ko)
Other versions
KR20040104572A (ko
Inventor
파스칼 가이야르
장-피에르 고델란트
피에르-알랭 비테
Original Assignee
라보라토리스 세로노 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토리스 세로노 에스.에이. filed Critical 라보라토리스 세로노 에스.에이.
Publication of KR20040104572A publication Critical patent/KR20040104572A/ko
Application granted granted Critical
Publication of KR100948469B1 publication Critical patent/KR100948469B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020047016871A 2002-04-25 2003-04-25 뇌경색 질환 또는 ｃｎｓ 질환의 치료를 위한 약물로서의피페라진 벤조티아졸 Expired - Fee Related KR100948469B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02100417 2002-04-25
EP02100417.1 2002-04-25
PCT/EP2003/004323 WO2003091249A1 (en) 2002-04-25 2003-04-25 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders

Publications (2)

Publication Number Publication Date
KR20040104572A KR20040104572A (ko) 2004-12-10
KR100948469B1 true KR100948469B1 (ko) 2010-03-17

Family

ID=29265991

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047016871A Expired - Fee Related KR100948469B1 (ko) 2002-04-25 2003-04-25 뇌경색 질환 또는 ｃｎｓ 질환의 치료를 위한 약물로서의피페라진 벤조티아졸

Country Status (22)

Country Link
US (1) US7314878B2 (enExample)
EP (1) EP1501828B1 (enExample)
JP (1) JP4523289B2 (enExample)
KR (1) KR100948469B1 (enExample)
CN (1) CN1310911C (enExample)
AT (1) ATE383356T1 (enExample)
AU (1) AU2003233067B2 (enExample)
BR (1) BRPI0309594A8 (enExample)
CA (1) CA2481763C (enExample)
CY (1) CY1107204T1 (enExample)
DE (1) DE60318567T2 (enExample)
DK (1) DK1501828T3 (enExample)
EA (1) EA009682B1 (enExample)
ES (1) ES2297165T3 (enExample)
IL (2) IL164796A0 (enExample)
MX (1) MXPA04010474A (enExample)
PT (1) PT1501828E (enExample)
RS (1) RS51407B (enExample)
SI (1) SI1501828T1 (enExample)
UA (1) UA78035C2 (enExample)
WO (1) WO2003091249A1 (enExample)
ZA (1) ZA200408023B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318567T2 (de) 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems
HRP20070527T3 (en) * 2003-09-12 2007-12-31 Laboratoires Serono Sa Benzothiazole derivatives for the treatment of diabetes
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
JP5144271B2 (ja) * 2004-11-17 2013-02-13 アレス トレーディング ソシエテ アノニム ベンゾチアゾ−ル製剤、及びそれらの使用
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
KR101368079B1 (ko) * 2008-05-16 2014-03-14 에프. 호프만-라 로슈 아게 Ｊｎｋ 의 억제제
CA2799328C (en) * 2010-06-04 2018-02-20 Humberto Bartolome Arzeno 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047920A1 (en) * 1999-12-24 2001-07-05 Applied Research Systems Ars Holding N.V. Benzazole derivatives and their use as jnk modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4153574B2 (ja) * 1997-09-10 2008-09-24 トーアエイヨー株式会社 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤
EP1193256A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
DE60318567T2 (de) 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047920A1 (en) * 1999-12-24 2001-07-05 Applied Research Systems Ars Holding N.V. Benzazole derivatives and their use as jnk modulators

Also Published As

Publication number Publication date
IL164796A (en) 2013-02-28
EP1501828B1 (en) 2008-01-09
US20050261304A1 (en) 2005-11-24
ZA200408023B (en) 2005-11-30
ES2297165T3 (es) 2008-05-01
SI1501828T1 (sl) 2008-04-30
DK1501828T3 (da) 2008-03-10
AU2003233067A1 (en) 2003-11-10
AU2003233067B2 (en) 2009-01-08
DE60318567D1 (de) 2008-02-21
CA2481763A1 (en) 2003-11-06
BRPI0309594A2 (pt) 2016-11-16
EA009682B1 (ru) 2008-02-28
RS92804A (sr) 2006-12-15
EP1501828A1 (en) 2005-02-02
CA2481763C (en) 2011-06-14
PT1501828E (pt) 2008-02-11
MXPA04010474A (es) 2004-12-13
EA200401423A1 (ru) 2005-04-28
WO2003091249A1 (en) 2003-11-06
KR20040104572A (ko) 2004-12-10
UA78035C2 (en) 2007-02-15
RS51407B (sr) 2011-02-28
CN1310911C (zh) 2007-04-18
BRPI0309594A8 (pt) 2017-04-11
ATE383356T1 (de) 2008-01-15
CY1107204T1 (el) 2012-11-21
JP2006504631A (ja) 2006-02-09
CN1662528A (zh) 2005-08-31
IL164796A0 (en) 2005-12-18
JP4523289B2 (ja) 2010-08-11
US7314878B2 (en) 2008-01-01
HK1075664A1 (en) 2005-12-23
DE60318567T2 (de) 2009-02-19

Similar Documents

Publication Publication Date Title
TWI235752B (en) Inhibitors of c-JUN N-terminal kinases (JNK) and other protein kinases
JP5693951B2 (ja) プロテインキナーゼの阻害剤
JP5379787B2 (ja) プロテインキナーゼの阻害剤
ES2289349T3 (es) Derivados de heteroaril-pirimidina como inhibidores de jak.
US20080255222A1 (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
JP4966958B2 (ja) カリウムチャネル調節剤及び医療における使用
JP5080241B2 (ja) Ｊｎｋ阻害剤およびスクロスポリンを含んでなる組成物
HRP20020496A2 (en) Benzazole derivatives and their use as jnk modulators
UA59403C2 (uk) Похідні ацилпіперазинілпіримідинів, спосіб їх одержання (варіанти), фармацевтична композиція та активний інгредієнт для виготовлення лікарського засобу
US7314878B2 (en) Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders
CN106831780A (zh) 具有cdk4/6和hdac抑制活性的新型杂环衍生物
CN108929312A (zh) 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
ES2401578T3 (es) Piridinilacetonitrilos
JP2004510772A (ja) タンパク質Ｊｕｎ−キナーゼのインヒビターとしての医薬的活性親水性スルホンアミド誘導体
JP4414219B2 (ja) Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）インヒビターとしてのアリールスルホンアミド誘導体
US7109220B2 (en) Amino substituted pyridinyl methanone compounds useful in treating kinase disorders
WO2025122501A1 (en) Benzothiophene-3-yl- and benzoselenophene-3-yl (biclyclic heteroaryl) malemides as gsk-3 inhibitors
CN106336412A (zh) 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
KR20200078921A (ko) N-아실유레아 유도체를 함유하는 평활근세포 증식, 부착 또는 이동 억제용 조성물
MXPA06011575A (en) Composition comprising a jnk inhibitor and cyclosporin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N234 Change of applicant [patent]: notification of change of applicant and registration of full transfer of right
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R14-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130312

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130312